From the perspective of tumor immunity, EMT is related to the dampening of CD4+ and CD8+ T cell responses by overexpression of TGF-β and IL-10, as well as the upregulation of immune checkpoints such as CTLA-4 and TIM-3 in lung carcinoma [20]. The gene discussed is TGFB1; the disease is neoplasm.